TARS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tarsus Pharmaceuticals is not a good buy right now for a beginner investor focused on long-term investing. The stock has weak short-term technical momentum, bearish trend structure, and no current AI Stock Picker or SwingMax buy signal. While the business outlook remains fundamentally promising and analyst firms are still constructive, the current setup is not attractive enough for an impatient buyer looking to enter now.
The technical picture is weak. MACD histogram is negative and expanding, showing downside momentum. RSI_6 at 32.88 is near oversold but not a strong reversal signal. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms a downtrend. Price at 59.12 is below the pivot of 62.572 and only slightly above S1 at 60.07 and S2 at 58.524, so support is fragile. The stock trend model also points to weakness, with a 70% chance of -3.42% next day, -14.18% next week, and -9.04% next month.
Oppenheimer and Mizuho both maintain Outperform ratings. Oppenheimer sees Tarsus as a successful commercial biotech story anchored by XDEMVY, with FY2025 net sales of $451.4M and 2026 guidance of $670M-$700M. Mizuho noted early approval for the Chinese partner Grand Pharma to commercialize TP-03 in Greater China, which is an incremental growth catalyst. Hedge funds have been buying aggressively, with buying amount up 987.14% over the last quarter.
No news was reported in the recent week, so there is no near-term news catalyst. Insiders have been selling heavily, with selling amount up 1503.33% over the last month. Technical momentum is weak, and options sentiment is bearish. The stock is also currently below the key pivot level.
Latest quarter financial data was not available due to an input error, so I cannot assess the most recent quarter directly. Based on the analyst commentary, the company has shown strong commercial growth, with FY2025 net sales of $451.4M and 2026 guidance of $670M-$700M, indicating continued top-line expansion. The latest quarter season was not provided.
Recent analyst trend remains positive overall but slightly more cautious on valuation. Oppenheimer initiated coverage with Outperform and a $98 target, down from $105, while Mizuho raised its target to $101 from $100 and kept Outperform. Wall Street pros are constructive on the long-term commercial story and launch execution, but the target cut from Oppenheimer suggests some moderation in near-term expectations.
